Did Ketamine 'Fail' or Are We Asking The Wrong Questions? *Full Study Review*

Access mentioned courses here:

Clinical Audit On Cognitive Aspects of Depression:

https://psychscene.co/3Z2EdvH

The Aggregation of Marginal Gains as a Philosophy of Clinical Care with Prof Michael Berk:

https://psychscene.co/4rqS62V

In this episode, Dr Sanil Rege examines the KARMA-Dep 2 trial, a randomised controlled trial comparing adjunctive serial ketamine infusions to midazolam for patients with Treatment-Resistant Depression (TRD) in an inpatient setting.

Based on a JAMA Psychiatry article titled “Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression,” the discussion explores why statistically insignificant differences between ketamine and psychoactive comparators necessitate a shift in how clinicians evaluate rapid-acting antidepressants, detailing the "wow effect" of early symptomatic drops and the subsequent plateauing of recovery curves.

This podcast provides clinicians with a clinical framework for differentiating between acute symptomatic response and long-term functional recovery in TRD.

Chapters:

00:22 - The KARMA-Dep 2 Trial Headlines
03:44 - Primary Outcomes: Ketamine vs. Midazolam Results
04:26 - Analysing the Curves: The "Wow Effect" vs. Sustained Recovery
08:50 - Neurobiology of Response vs. Neurobiology of Recovery
09:21 - Why Improvement Stalls: The Role of Neuroadaptation
10:47 - Clinical Implications for Inpatient Care

To get access to more materials like this plus over 150 hours of interactive CPD education on psychiatry, check out The Academy using the link below:

https://psychscene.co/4rl6pFV